Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Minty colonoscopy rinse could boost cancer detection

NCT ID NCT07501975

Diagnosis Sponsor: The First Affiliated Hospital of Zhengzhou University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial tests a special rinse solution containing menthol (from peppermint) and simethicone (a defoamer) during colonoscopy. The goal is to reduce muscle spasms and clear bubbles, giving doctors a better view to find precancerous polyps. About 500 adults undergoing colonoscopy will be randomly assigned to get the new rinse or standard saline. The main measure is how many polyps are found.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
0.1% menthol solution combined with simethicone aqueous suspension
What this could lead to
If it works, this could make colonoscopies more comfortable and effective at finding polyps, potentially improving early cancer detection.
What could go wrong
This is an early-stage trial with no phase designation, so results are uncertain. The solution may not significantly improve detection or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 498 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age between 18 and 75 years, regardless of gender; 2. Scheduled to undergo colonoscopy (for screening, diagnostic, or follow-up purposes); 3. Adequate bowel preparation quality (Boston Bowel Preparation Scale score ≥ 6); 4. Voluntarily signed informed consent and able to cooperate with completing study-related assessments. Exclusion Criteria: 1. Allergy to menthol, cyclodextrin, or related substances; 2. History of severe intestinal diseases (such as ulcerative colitis, Crohn's disease, intestinal perforation, intestinal obstruction, intestinal tumors, etc.); 3. Presence of severe dysfunction of vital organs such as the heart, liver, kidneys, or lungs, or coagulation disorders; 4. Pregnant or lactating women; 5. Use of anticholinergic drugs, calcium channel blockers, or other spasmolytic agents within one week prior to the examination; 6. Psychiatric disorders or cognitive impairment that prevent cooperation with the study; 7. History of contraindications to colonoscopy or serious adverse reactions during previous procedures.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colonoscopy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colonoscopy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.